Mid-term outcomes from a multicenter study: Is TEVAR safe for ascending aortic dissection?

Area of Science:

• Cardiovascular Surgery
• Vascular Surgery
• Interventional Cardiology

Background:

• Thoracic endovascular aortic repair (TEVAR) is utilized for type A aortic dissection (TAAD).
• Existing outcome data for TEVAR in TAAD varies due to differing sample sizes and methodologies.
• This study addresses the need for consistent, mid-term outcome data in a Chinese cohort.

Purpose of the Study:

• To evaluate the mid-term efficacy and safety of TEVAR for treating TAAD.
• To analyze early and late postoperative outcomes and complications.
• To assess survival rates following TEVAR in a cohort of TAAD patients.

Main Methods:

• A retrospective analysis of 56 TAAD patients treated with TEVAR between 2001 and 2015.
• Data collected from five medical centers in China.
• Morphological changes, early (≤30 days), and late outcomes were recorded and analyzed.

Main Results:

• Technical success rate of 96.43% in 56 TAAD patients (aged 38-80).
• 30-day survival rate was 92.9%, with 7 early complications including death (1) and cerebral infarction (3).
• 5-year survival was 80.9% (98.2% excluding aorta-related deaths), with late events including retrograde dissection (8) and endoleak (5).

Conclusions:

• TEVAR presents a viable alternative treatment for high-risk TAAD patients.
• While effective, TEVAR necessitates vigilant attention to postoperative complications.
• Further research into managing TEVAR-related complications is warranted.